Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Am J Hematol. 2011 Sep;86(9):811–819. doi: 10.1002/ajh.22097

Table III.

Candidate agents in investigation, for patients with BCR-ABL1 positive leukemias intolerant/refactory/resistant to second generation TKIs or harboring the T315 mutantion.

Novel kinase inhibitors
    • Ponatinib (AP24534)
    • DCC-2036
    • PHA-739258

Omacetaxine (Homoharingtonine)
Other approaches
    • HSP-90 inhibitors
    • Histone deacetylase inhibitors